The mission of the Drug Enforcement Administration’s (DEA) Diversion Control Division is to prevent, detect, and investigate the diversion of controlled pharmaceuticals and listed chemicals from legitimate sources while ensuring an adequate and uninterrupted supply for legitimate medical, commercial, and scientific needs.
During this National Emergency the Diversion Control Division will continue to work with our Federal partners, DEA registrants, and their representative association to assure that there is an adequate supply of controlled substances in the United States. The DEA will also work to assure that patients will have access to controlled substances.
On March 16, 2020, the DEA published a COVID-19 Information Page on the Diversion Control Divisions Website: https://www.deadiversion.usdoj.gov/coronavirus.html
This page contains important guidance concerning COVID-19 and the national drug supply, electronic prescribing of controlled substances, telemedicine, medicated assisted treatment, and other important federal and state information. This site will be updated frequently as new information and guidance is issued. Please check back frequently for further information.
Please continue to direct all policy questions concerning COVID-19 to the Policy email box at Natural.Disaster@usdoj.gov
In addition, effective March 23, 2020, the DEA Call Center has temporarily suspended phone operations due to COVD-19 health epidemic. Assistance will only be available through DEA.Registration.Help@usdoj.gov. We will respond to your emails as quickly as possible.
Please register your e-mail address using the below link to obtain up to date information concerning DEA’s response to the COVID-19 health emergency.
https://public.govdelivery.com/accounts/USDOJDEADCD/subscriber/new
Please continue to direct all policy questions concerning COVID-19 to the Policy email box at Natural.Disaster@usdoj.gov